SCHEMBL25923261

SCHEMBL25923261

CCNCCc1ccc(CNCC(C)C)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.53
GAA P10253 2/20 0.44
MAPT P10636 1/20 0.44
LMNA P02545 2/20 0.42
OPRM1 P35372 1/20 0.40
OPRK1 P41145 1/20 0.40
CA2 P00918 4/20 0.40
CA12 O43570 2/20 0.40
CA1 P00915 2/20 0.40
CA9 Q16790 2/20 0.40
ALDH1A1 P00352 3/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
S1PR2 O95136 2/20 0.38
S1PR4 O95977 2/20 0.38
S1PR1 P21453 2/20 0.38
S1PR3 Q99500 2/20 0.38
BCHE P06276 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24673819 0.87 L3MBTL1 (0.44) L3MBTL1LMNAOPRM1OPRK1CA2
SCHEMBL22856392 0.84 L3MBTL1 (0.46) L3MBTL1GAAMAPTLMNAOPRM1
SCHEMBL22794506 0.84 TAAR1 (0.50) L3MBTL1GAAMAPTLMNAOPRM1
SCHEMBL21655058 0.83 L3MBTL1 (0.53) L3MBTL1LMNAALDH1A1CYP1A2CYP2C19
SCHEMBL23945588 0.83 L3MBTL1 (0.42) L3MBTL1GAAMAPTOPRM1OPRK1
SCHEMBL23945721 0.82 L3MBTL1 (0.45) L3MBTL1GAAMAPTLMNAOPRM1
SCHEMBL25883717 0.81 L3MBTL1 (0.44) L3MBTL1GAAMAPTOPRM1OPRK1
SCHEMBL25479303 0.81 LMNA (0.57) L3MBTL1GAAMAPTLMNAOPRM1
SCHEMBL2242597 0.78 TAAR1 (0.52) L3MBTL1OPRM1OPRK1CA2ALDH1A1
Hydrochloric Acid SCHEMBL28573233 0.78 SIGMAR1 (0.42) L3MBTL1GAAMAPTCA2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234953-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234953-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 L3MBTL1 1394/4885GAA 1234/4885MAPT 2459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.